Definitive Healthcare (NASDAQ:DH) Stock Rating Lowered by Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Several other equities analysts also recently commented on the stock. Morgan Stanley reissued an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a research report on Thursday, December 18th. Barclays decreased their price objective on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a report on Monday, December 8th. William Blair raised Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. Canaccord Genuity Group cut their price target on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday. Finally, Stephens lowered their price objective on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.52.

Definitive Healthcare Price Performance

NASDAQ DH opened at $1.28 on Friday. The stock has a market capitalization of $180.94 million, a PE ratio of -1.02 and a beta of 1.59. The company has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $2.88. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41. Definitive Healthcare has a 12-month low of $1.14 and a 12-month high of $4.70.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in DH. New York State Common Retirement Fund raised its position in Definitive Healthcare by 0.4% in the 2nd quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock valued at $2,989,000 after purchasing an additional 3,066 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Definitive Healthcare by 32.9% in the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock worth $72,000 after acquiring an additional 4,407 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after purchasing an additional 5,970 shares in the last quarter. Invesco Ltd. lifted its position in shares of Definitive Healthcare by 5.8% during the fourth quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock worth $337,000 after purchasing an additional 6,400 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Definitive Healthcare during the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Key Stories Impacting Definitive Healthcare

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.